BIOG — Biotech Growth Trust Income Statement
0.000.00%
Last trade - 00:00FinancialsBalancedSmall Cap
- £241.31m
- £232.85m
- -£77.53m
Annual income statement for Biotech Growth Trust, fiscal year end - March 31st, GBP millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 226 | -207 | -36.2 | 79.7 | -77.5 |
| Cost of Revenue | |||||
| Gross Profit | 201 | -201 | -40.5 | 75.5 | -81.9 |
| Selling / General / Administrative Expenses | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 24.9 | -5.02 | 5.07 | 4.97 | 4.98 |
| Operating Profit | 201 | -202 | -41.2 | 74.8 | -82.5 |
| Net Income Before Taxes | 201 | -202 | -41.2 | 74.8 | -82.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 200 | -202 | -41.3 | 74.6 | -82.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 200 | -202 | -41.3 | 74.6 | -82.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 200 | -202 | -41.3 | 74.6 | -82.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 5 | -4.88 | -1.03 | 2.07 | -2.62 |